Biosimilars
•11 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (11)
| Company | Market Cap | Price |
|---|---|---|
|
ABT
Abbott Laboratories
Abbott's biosimilars pipeline signals growth potential in biosimilar therapeutics, aligning with the Biosimilars investable theme.
|
$210.13B |
$108.62
-10.03%
|
|
AMGN
Amgen Inc.
Amgen maintains a significant Biosimilars portfolio with multiple launches since 2018.
|
$184.98B |
$347.11
+1.02%
|
|
VTRS
Viatris Inc.
Viatis pursues biosimilar opportunities alongside its generics portfolio.
|
$15.21B |
$13.25
+1.53%
|
|
RDY
Dr. Reddy's Laboratories Limited
Significant emphasis on biosimilar development and commercialization.
|
$10.76B |
$13.71
+3.20%
|
|
AMRX
Amneal Pharmaceuticals, Inc.
Amneal is expanding into biosimilars, a core diversification from traditional generics.
|
$4.31B |
$13.56
-1.06%
|
|
OGN
Organon & Co.
Biosimilars portfolio (Hadlima, Renflexis, Ontruzant, Tofidence) represents a major product line.
|
$2.49B |
$9.73
+1.51%
|
|
HROW
Harrow Health, Inc.
Strategic biosimilars portfolio in ophthalmology (BYOOVIZ, OPUVIZ) with Samsung Bioepis.
|
$1.74B |
$45.35
-3.76%
|
|
AMPH
Amphastar Pharmaceuticals, Inc.
Amphastar is advancing biosimilar programs (AMP-004) and positions biosimilars as a core growth pillar.
|
$1.22B |
$26.13
-0.34%
|
|
KMDA
Kamada Ltd.
Biosimilar product distribution is a key existing business line for Kamada's expanded portfolio.
|
$447.96M |
$8.00
+2.63%
|
|
RANI
Rani Therapeutics Holdings, Inc.
RT-111 and RT-105 include ustekinumab and adalimumab biosimilars, fitting the biosimilars category.
|
$97.02M |
$1.40
+3.33%
|
|
SCNX
Scienture Holdings, Inc.
SCN-106 is described as a potential biosimilar, fitting the Biosimilars investable theme.
|
$8.23M |
$0.50
-2.49%
|
Loading company comparison...
Loading industry trends...
Loading research report...
